Cargando…
Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
The protein p53, known as the “Guardian of the Genome”, plays an important role in maintaining DNA integrity, providing protection against cancer-promoting mutations. Dysfunction of p53 is observed in almost every cancer, with 50% of cases bearing loss-of-function mutations/deletions in the TP53 gen...
Autores principales: | Kocik, Justyna, Machula, Monika, Wisniewska, Aneta, Surmiak, Ewa, Holak, Tad A., Skalniak, Lukasz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678622/ https://www.ncbi.nlm.nih.gov/pubmed/31331108 http://dx.doi.org/10.3390/cancers11071014 |
Ejemplares similares
-
Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists
por: Neochoritis, Constantinos G, et al.
Publicado: (2019) -
PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
por: Surmiak, Ewa, et al.
Publicado: (2021) -
Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
por: Skalniak, Lukasz, et al.
Publicado: (2018) -
Human and mouse PD-L1: similar molecular structure, but different druggability profiles
por: Magiera-Mularz, Katarzyna, et al.
Publicado: (2020) -
Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies
por: Rodriguez, Ismael, et al.
Publicado: (2023)